APOE-ε4 modulates the association among plasma Aβ42/Aβ40, vascular diseases, neurodegeneration and cognitive decline in non-demented elderly adults
Authors:
- Tengfei GuoTGTengfei Guo
- For The Alzheimer’s Disease Neuroimaging InitiativeFIFor The Alzheimer’s Disease Neuroimaging Initiative
Open Access
- 29 March 2022
- journal article
- research article
- Published by Springer Nature in Translational Psychiatry
- Vol. 12 (1) , 1-9
Abstract
Including apolipoprotein E-ε4 (APOE-ε4) status and older age into consideration may increase the accuracy of plasma Aβ42/Aβ40 detecting Aβ+ individuals, but the rationale behind this remains to be fully understood. Besides, both Aβ pathology and vascular diseases are related to neurodegeneration and cognitive decline, but it is still not fully understood how APOE-ε4 modulates these relationships. In this study, we examined 241 non-demented Alzheimer’s Disease Neuroimaging Initiative participants to investigate the associations among age, white matter hyperintensities (WMH), hypertension, hyperlipidemia, body mass index (BMI), plasma Aβ42/Aβ40 measured by liquid chromatography tandem mass spectrometry, and 18F-florbetapir Aβ PET as well as their prediction of longitudinal adjusted hippocampal volume (aHCV) and cognition in APOE-ε4 carriers and non-carriers. We found older age predicted faster WMH increase (p = 0.024) and cortical Aβ accumulation (p = 0.043) in APOE-ε4 non-carriers only, whereas lower plasma Aβ42/Aβ40 predicted faster cortical Aβ accumulation (p < 0.018) regardless of APOE-ε4 status. While larger WMH and underweight predicted (p < 0.05) faster decreases in aHCV and cognition in APOE-ε4 non-carriers, lower plasma Aβ42/Aβ40 predicted (p < 0.031) faster decreases in aHCV and cognition in APOE-ε4 carriers. Higher Aβ PET also predicted faster rates of aHCV (p = 0.010) in APOE-ε4 carriers only, but was related to faster rates of cognitive decline (p < 0.022) regardless of APOE-ε4 status. These findings may provide novel insights into understanding different mechanisms underlie neurodegeneration and cognitive decline in non-demented elderly adults with and without APOE-ε4 allele, which may help the design of anti-Alzheimer’s clinical trials.Keywords
Funding Information
- National Natural Science Foundation of China (82171197)
This publication has 57 references indexed in Scilit:
- The Preclinical Alzheimer Cognitive CompositeJAMA Neurology, 2014
- Effects of APOE ɛ4 on brain amyloid, lacunar infarcts, and white matter lesions: a study among patients with subcortical vascular cognitive impairmentNeurobiology of Aging, 2013
- White matter hyperintensities predict amyloid increase in Alzheimer's diseaseNeurobiology of Aging, 2012
- Vascular burden and Alzheimer disease pathologic progressionNeurology, 2012
- Cerebrovascular disease, beta-amyloid, and cognition in agingNeurobiology of Aging, 2012
- White Matter Lesions Are Not Related toβ-Amyloid Deposition in an Autopsy-Based StudyCurrent Gerontology and Geriatrics Research, 2011
- An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer diseaseAnnals of Neurology, 2011
- Factors affecting Aβ plasma levels and their utility as biomarkers in ADNIActa Neuropathologica, 2011
- Longitudinal Changes in White Matter Disease and Cognition in the First Year of the Alzheimer Disease Neuroimaging InitiativeArchives of Neurology, 2010
- Ten-Year Change in Plasma Amyloid β Levels and Late-Life Cognitive DeclineArchives of Neurology, 2009